222 related articles for article (PubMed ID: 12401719)
1. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.
Forbes JM; Cooper ME; Thallas V; Burns WC; Thomas MC; Brammar GC; Lee F; Grant SL; Burrell LM; Jerums G; Osicka TM
Diabetes; 2002 Nov; 51(11):3274-82. PubMed ID: 12401719
[TBL] [Abstract][Full Text] [Related]
2. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Jerums G; Panagiotopoulos S; Forbes J; Osicka T; Cooper M
Arch Biochem Biophys; 2003 Nov; 419(1):55-62. PubMed ID: 14568009
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Coughlan MT; Thallas-Bonke V; Pete J; Long DM; Gasser A; Tong DC; Arnstein M; Thorpe SR; Cooper ME; Forbes JM
Endocrinology; 2007 Feb; 148(2):886-95. PubMed ID: 17110423
[TBL] [Abstract][Full Text] [Related]
4. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Wihler C; Schäfer S; Schmid K; Deemer EK; Münch G; Bleich M; Busch AE; Dingermann T; Somoza V; Baynes JW; Huber J
Diabetologia; 2005 Aug; 48(8):1645-53. PubMed ID: 16010524
[TBL] [Abstract][Full Text] [Related]
5. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
6. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.
Wilkinson-Berka JL; Kelly DJ; Koerner SM; Jaworski K; Davis B; Thallas V; Cooper ME
Diabetes; 2002 Nov; 51(11):3283-9. PubMed ID: 12401720
[TBL] [Abstract][Full Text] [Related]
7. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats.
Soulis T; Cooper ME; Sastra S; Thallas V; Panagiotopoulos S; Bjerrum OJ; Jerums G
Diabetologia; 1997 Oct; 40(10):1141-51. PubMed ID: 9349594
[TBL] [Abstract][Full Text] [Related]
8. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.
Soulis T; Cooper ME; Vranes D; Bucala R; Jerums G
Kidney Int; 1996 Aug; 50(2):627-34. PubMed ID: 8840295
[TBL] [Abstract][Full Text] [Related]
9. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.
Gilbert RE; Cox A; Wu LL; Allen TJ; Hulthen UL; Jerums G; Cooper ME
Diabetes; 1998 Mar; 47(3):414-22. PubMed ID: 9519748
[TBL] [Abstract][Full Text] [Related]
10. Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats.
Osicka TM; Kiriazis Z; Pratt LM; Jerums G; Comper WD
Diabetologia; 2001 Feb; 44(2):230-6. PubMed ID: 11270681
[TBL] [Abstract][Full Text] [Related]
11. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
Forbes JM; Thorpe SR; Thallas-Bonke V; Pete J; Thomas MC; Deemer ER; Bassal S; El-Osta A; Long DM; Panagiotopoulos S; Jerums G; Osicka TM; Cooper ME
J Am Soc Nephrol; 2005 Aug; 16(8):2363-72. PubMed ID: 15930093
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia in the diabetic kidney is independent of advanced glycation end-products.
Nordquist L; Liss P; Fasching A; Hansell P; Palm F
Adv Exp Med Biol; 2013; 765():185-193. PubMed ID: 22879032
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Thallas-Bonke V; Lindschau C; Rizkalla B; Bach LA; Boner G; Meier M; Haller H; Cooper ME; Forbes JM
Diabetes; 2004 Nov; 53(11):2921-30. PubMed ID: 15504973
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN).
Yuan Y; Sun H; Sun Z
Lipids Health Dis; 2017 Jun; 16(1):126. PubMed ID: 28659153
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective effects of a novel inhibitor of advanced glycation.
Forbes JM; Soulis T; Thallas V; Panagiotopoulos S; Long DM; Vasan S; Wagle D; Jerums G; Cooper ME
Diabetologia; 2001 Jan; 44(1):108-14. PubMed ID: 11206401
[TBL] [Abstract][Full Text] [Related]
16. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
[TBL] [Abstract][Full Text] [Related]
17. The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.
De Blasio MJ; Ramalingam A; Cao AH; Prakoso D; Ye JM; Pickering R; Watson AMD; de Haan JB; Kaye DM; Ritchie RH
Eur J Pharmacol; 2017 Jul; 807():12-20. PubMed ID: 28438648
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli.
Sugimoto H; Shikata K; Wada J; Horiuchi S; Makino H
Diabetologia; 1999 Jul; 42(7):878-86. PubMed ID: 10440132
[TBL] [Abstract][Full Text] [Related]
19. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation.
Tilton RG; Chang K; Hasan KS; Smith SR; Petrash JM; Misko TP; Moore WM; Currie MG; Corbett JA; McDaniel ML
Diabetes; 1993 Feb; 42(2):221-32. PubMed ID: 7678825
[TBL] [Abstract][Full Text] [Related]
20. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery.
Osicka TM; Yu Y; Lee V; Panagiotopoulos S; Kemp BE; Jerums G
Clin Sci (Lond); 2001 Mar; 100(3):249-57. PubMed ID: 11222110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
